---
schema_version: "secwatch.filing_event.v1"
accession: "0001855644-26-000007"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2026-08-11T11:35:33+00:00"
generated_at: "2026-08-11T11:40:06.313024+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zura Bio completes enrollment in two Phase 2 tibulizumab trials; cash $205.1M

## Summary
- TibuSHIELD (hidradenitis suppurativa) enrolled 247 participants, exceeding target; topline data Q4 2026.
- TibuSURE (systemic sclerosis) enrolled 91 participants, exceeding target; topline data H1 2027.
- New indication: plans Phase 2 NEXUS-PMR for polymyalgia rheumatica by year-end 2026.
- Q2 2026 net loss $26.3M ($0.21/share) vs $16.0M ($0.17/share) in Q2 2025; R&D expenses $20.7M vs $8.7M.
- Cash and equivalents $205.1M expected to fund operations through at least end of 2028.

## SEC filing metadata
- accession: 0001855644-26-000007
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2026-08-11T11:35:33+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/0001855644-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/zura-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001855644-26-000007
- JSON: https://secwatch.observer/filing/0001855644-26-000007.json
- Plain text: https://secwatch.observer/filing/0001855644-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.